The effect of TCAs on CYP2D6 activity in vivo

被引：0
|
作者：
Szewczuk-Boguslawska, M. [1 ]
Kiejna, A. [1 ]
Beszlej, J. [1 ]
Orzechowska-Juzwenko, K. [1 ]
机构：
[1] Univ Med, Wroclaw, Poland
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [11] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [12] The influence of clomipramine on CYP2D6 activity
    Szewczuk-Boguslawska, Monika
    Kiejna, Andrzej
    Grzesiak, Magdalena
    Beszlej, Jan Aleksander
    Chlebowska, Iwona
    Orzechowska-Juzwenko, Krystyna
    Milejski, Piotr
    PSYCHIATRIA POLSKA, 2007, 41 (02) : 243 - 249
  • [13] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Tolledo, Cole
    Stocco, Marlaina R.
    Miksys, Sharon
    Gonzalez, Frank J.
    Tyndale, Rachel F.
    MOLECULAR NEUROBIOLOGY, 2020, 57 (06) : 2509 - 2520
  • [14] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [15] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Cole Tolledo
    Marlaina R. Stocco
    Sharon Miksys
    Frank J. Gonzalez
    Rachel F. Tyndale
    Molecular Neurobiology, 2020, 57 : 2509 - 2520
  • [16] Role of CYP2D6 in the demethylation of fluoxetine in vivo
    Hamelin, BA
    Turgeon, J
    Vallee, F
    Belanger, PM
    Paquet, F
    LeBel, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI33 - PI33
  • [17] Investigation of terbinafine as a CYP2D6 inhibitor in vivo
    Abdel-Rahman, SM
    Gotschall, RR
    Kauffman, RE
    Leeder, JS
    Kearns, GL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) : 465 - 472
  • [18] Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10
    Doki, Kosuke
    Shirayama, Yuki
    Sekiguchi, Yukio
    Aonuma, Kazutaka
    Kohda, Yukinao
    Ieda, Masaki
    Homma, Masato
    PHARMACOGENOMICS, 2020, 21 (18) : 1279 - 1288
  • [19] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [20] EFFECT OF AGE AND GENOTYPE ON CYP2D6 ACTIVITY IN CHILDREN AND ADOLESCENTS
    Gaedigk, Andrea
    Pearce, Robin E.
    Tay-Sontheimer, Jessica
    Thummel, Kenneth E.
    Lin, Yvonne S.
    Leeder, J. Steven
    DRUG METABOLISM REVIEWS, 2015, 47 : 84 - 85
12345